Abstract
Apoptosis or progress of programmed cell death is a tightly regulated process which plays an important role in various cardiovascular diseases particularly in myocardial infarction, reperfusion injury, and heart failure. Over the past two decades, investigations of several pathways have broadened our understanding of programmed cell death. Many anti-apoptotic interventions have targeted ischemia- reperfusion, however only a limited number have been considered at the chronic stage of heart failure. Endogenous inhibitors, caspase inhibitors, PARP-1 inhibitors, as well as various other agents have been implicated as anti-apoptotic interventions. This review summarizes the apoptotic pathways associated with heart failure, discusses the current anti-apoptotic interventions available and reviews the clinical implications.
Keywords: Apoptosis, Heart failure, Caspase inhibitors, Endogenous inhibitors, Anti-apoptotic interventions, Caspase, Endogenous, zymogens, Cardiovascular, congestive, executioner, hypertrophy, diabetes, systolic, reperfusion, myocardial, mitochondrial, proteases
Current Pharmaceutical Design
Title: Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Volume: 17 Issue: 18
Author(s): Sylvia S. Singh and Peter M. Kang
Affiliation:
Keywords: Apoptosis, Heart failure, Caspase inhibitors, Endogenous inhibitors, Anti-apoptotic interventions, Caspase, Endogenous, zymogens, Cardiovascular, congestive, executioner, hypertrophy, diabetes, systolic, reperfusion, myocardial, mitochondrial, proteases
Abstract: Apoptosis or progress of programmed cell death is a tightly regulated process which plays an important role in various cardiovascular diseases particularly in myocardial infarction, reperfusion injury, and heart failure. Over the past two decades, investigations of several pathways have broadened our understanding of programmed cell death. Many anti-apoptotic interventions have targeted ischemia- reperfusion, however only a limited number have been considered at the chronic stage of heart failure. Endogenous inhibitors, caspase inhibitors, PARP-1 inhibitors, as well as various other agents have been implicated as anti-apoptotic interventions. This review summarizes the apoptotic pathways associated with heart failure, discusses the current anti-apoptotic interventions available and reviews the clinical implications.
Export Options
About this article
Cite this article as:
S. Singh Sylvia and M. Kang Peter, Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases, Current Pharmaceutical Design 2011; 17 (18) . https://dx.doi.org/10.2174/138161211796390994
DOI https://dx.doi.org/10.2174/138161211796390994 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker
Cardiovascular & Hematological Agents in Medicinal Chemistry Caveolin-3: Its Importance in Muscle Function and Pathology
Current Genomics Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?
Current Vascular Pharmacology Propofol Promotes Blood-Brain Barrier Breakdown and Heat Shock Protein (HSP 72 kd) Activation in the Developing Mouse Brain
CNS & Neurological Disorders - Drug Targets Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease
Current Pharmaceutical Design Insight γ-Secretase: Structure, Function, and Role in Alzheimer’s Disease
Current Drug Targets "Take and Run" and "Take and Hold" Therapeutical Electromagnetic Field Application Modalities in Physiotherapy: Some Clinically Significant Pathways of Action
Current Chemical Biology Updates on HCN Channels in the Heart: Function, Dysfunction and Pharmacology
Current Drug Targets The Emerging Role of MicroRNA in Schizophrenia
CNS & Neurological Disorders - Drug Targets The Chick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-Angiogenesis
Current Pharmaceutical Biotechnology The Effect of a Four-Week Balance Training Program on Anticipatory Postural Adjustments in Older Adults: A Pilot Feasibility Study
Current Aging Science Recently Patented Applications of Homologous Cellular and Extracellular Agents as Therapeutics or Targets for the Prevention of Restenosis Post- Angioplasty
Recent Patents on Cardiovascular Drug Discovery Targeting ADAM12 in Human Disease: Head, Body or Tail?
Current Pharmaceutical Design Role of Mechanical Stress in Monocytes / Macrophages: Implications for Atherosclerosis
Current Vascular Pharmacology The Adipocyte as a Novel TSH Target
Mini-Reviews in Medicinal Chemistry Medication Adherence and Associated Factors among Chronic Heart Failure Clients on Follow Up Oromia Region, West Ethiopia
Cardiovascular & Hematological Agents in Medicinal Chemistry A Review on the Neuroprotective Effect of Berberine against Chemotherapy- induced Cognitive Impairment
Current Drug Targets Therapies of Hematological Malignancies: An Overview of the Potential Targets and Their Inhibitors
Current Chemical Biology Metabolic Features Across the Female Life Span in Women with PCOS
Current Pharmaceutical Design Adrenomedullin in Heart Failure: Molecular Mechanism and Therapeutic Implication
Current Hypertension Reviews